CN102050864B - Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof - Google Patents
Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof Download PDFInfo
- Publication number
- CN102050864B CN102050864B CN 201010555974 CN201010555974A CN102050864B CN 102050864 B CN102050864 B CN 102050864B CN 201010555974 CN201010555974 CN 201010555974 CN 201010555974 A CN201010555974 A CN 201010555974A CN 102050864 B CN102050864 B CN 102050864B
- Authority
- CN
- China
- Prior art keywords
- glucopyranosyl
- beta
- wild ginseng
- ginseng
- extraction method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to a transplanted wild ginseng ginsenoside B as well as an extraction method and medical application thereof, belonging to the medical field. The extraction method comprises the following steps of: crushing a dry transplanted wild ginseng root, heating with ethanol for backflow and extraction, concentrating under reduced pressure, extracting to obtain an n-butyl alcohol part, then separating, purifying to obtain the transplanted wild ginseng ginsenoside B. The transplanted wild ginseng ginsenoside B is applied to preparing medicaments for treating myocardial ischemia, hemorrhagic shock, arrhythmia and reperfusion injury.
Description
Technical field
The present invention relates to 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl and extracting method thereof, and its application in preparation treatment myocardial ischemia, ischemic shock, arrhythmia and reperfusion injury medicine.
Background technology
The wild ginseng of the Northeast is well-known, and not only domestic situation of selling well is also quite sold well in the world.Because expensive, a large amount of predatorinesses of people are excavated, and make the wild ginseng resource fewer and feweri, be on the verge of disappearance.In the situation that supply-demand imbalance, the mid-80 is cultivated garden ginsent in a large number.The deforestation seed ginseng though alleviated the demand of market to ginseng, owing to having changed the forest environment of Ginseng Growth, is added and is used chemical fertilizer, sprays insecticide etc., causes constituent of ginseng to change, and the efficacy of a drug weakens, and residual the exceeding standard of farming loses original medicinal function.China's ginseng once found no sale in the international market, and price is kept falling, and in addition, the overdevelopment garden ginsent has also caused destruction to ecotope, causes forest resource decrease, severe water and soil erosion.After country implemented " Natural Forest Protection Project ", the ginseng price began to go up.Under the prerequisite that effectively protects forest resources, cultivating the ginseng under forest similar to wild ginseng becomes the task of top priority.
Nineteen sixties, the Fu Song county, township of panax ginseng in jiljn took the lead in planting experimentally " Ginseng under Forest ", begin one after another to set up the base and cultivate " Ginseng under Forest " to the state-run ginseng such as the eighties Jilin, Liaoning, Heilungkiang factory, ginseng factory of collective, up to the present, only China the Northeast " Ginseng under Forest " area is with regard to approximately more than 50 ten thousand mu, can provide to market more than 2,000 kilogram of Ginseng under Forest every year, more than 500 kilogram of conversion dry product, the cultivation of Ginseng under Forest, plantation and popularization make the wild ginseng resource obtain historical recovery.
Ginseng under Forest (Panax ginseng C.A.Meyer cv.Silvatica), also claim " sylvan life seed ", " seed goods " is that manual type is sowed the garden ginsent seed in remote, thickly forested mountains, seed germinates naturally, in wild environment self-sow, make goods through gathering again after the several years.New edition pharmacopeia in 2005, name be " Ginseng under Forest ", 2006, be revised as " ginseng under forest ".It is a kind of high efficiency composition Eco-economy System pattern that ginseng is cultivated in sylvan life, and the area of deforestation seed ginseng will be controlled and reduce to its development effectively, alleviates high economic benefit ginseng planting already and the contradiction between the forestry of high ecological benefits.This mode all has great importance for the development of the Sustainable development that promotes the forest reserves and the production of ginseng industry.The fundamental research of Ginseng under Forest is still a blank at present, and along with die-offing of wild ginseng quantity, the Ginseng under Forest plantation is increasingly extensive with application, and the research of carrying out this respect is imperative.
Summary of the invention
The invention provides 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl and extracting method thereof and its pharmaceutical use.
White powder (CH
3OH), mp:180 ℃～182 ℃.The Liebermann-Burchard reaction is positive, and the Molish reaction is positive.10% sulphuric acid hydrolysis PC detects glucose.From Ginseng under Forest, to separate the monomeric compound that obtains, therefore the called after 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl.Chemical name is 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-11,12-epoxy-Da Ma-20S, 24S-epoxy-3 β, 12 β, the 25-triol (3-O-[β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl]-11,12-epoxy-dammar-20S, 24S-epoxy-3 β, 12 β, 25-triol).
The preparation method of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl comprises the following steps: among the present invention
A, extraction: get dry Ginseng under Forest root 1.4kg, pulverize, extract 3 times with 65%～85% alcohol heating reflux, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use respectively successively sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction, decompression and solvent recovery gets propyl carbinol part 100～120g to doing.
B, separation: be that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly with the propyl carbinol that obtains, adopt the volume ratio trichloromethane: the eluent of methyl alcohol=8: 1～8 carries out wash-out, collect 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl part elutriant, reclaim solvent and get the thick product of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl, yield 0.013～0.019%;
The purifying of c, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl: the 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl crude product that separation obtains also can adopt the recrystallizing methanol method to carry out purifying by again carrying out column chromatography purification or preparative liquid chromatography purifying, can get approximately 0.2g～0.3g of pure 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl.
At present do not see the extracting method of relevant 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl and the report of compound, this compound belongs to new compound, belongs to separate first to obtain; The pharmaceutical use that this compound is new belongs to first to be found.
The present invention can be used for preparation treatment coronary heart disease, myocardial ischemia, ischemic shock, the medicines such as arrhythmia and reperfusion injury.Its oral or parenteral admin, all be safe, in oral situation, it can any conventionally form administration, such as powder, granula, tablet, capsule, pill, solution, suspension, syrup, buccal tablets, sublingual lozenge etc.: when this medicine administered parenterally, can take any conventionally form, such as injection: such as intravenous injection, ointment, suppository, percutaneous dosing, inhalation etc.
The medicine that the present invention prepares treatment coronary heart disease, myocardial ischemia, ischemic shock, arrhythmia and reperfusion injury is to be made of effective constituent monomer or the effective constituent vehicle with solid or liquid, the vehicle of solid used herein or liquid is well known in the art, the below lifts several object lessons, powder is the powder agent that takes orally, its vehicle has lactose, starch, paste essence, calcium carbonate, synthetic or puritan filler aluminium, magnesium oxide, Magnesium Stearate, sodium bicarbonate, dry yeast etc.; The vehicle of solution has water, glycerine, 1,2-PD, simple syrup, ethanol, ethylene glycol, polyoxyethylene glycol, Sorbitol Powder etc.; The vehicle of ointment can use fatty oil, and hydrous wool, Vaseline, glycerine, honeybee are cured, wood is cured, white oil, resin, senior hydrophobizing agent or the hydrophilizing agent that is combined into such as cured.
Beneficial effect of the present invention is, the new compound 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl can be used for preparation treatment coronary heart disease, myocardial ischemia, and ischemic shock, the medicine of arrhythmia and reperfusion injury has characteristics evident in efficacy.
The dosage of active substance can be according to taking mode, and patient's age and body weight and coincident with severity degree of condition change with other similar factor, and oral dose is: 9.0～16.0mg/kg, and every twice-daily is taken: injection 7.0～9.0mg/kg, once a day.
Description of drawings
Fig. 1 is of the present invention
1The HNMR spectrogram;
Fig. 2 is of the present invention
13The CNMR spectrogram;
Fig. 3 is ESI-MS spectrogram of the present invention.
Embodiment
Embodiment 1:
A, extraction: get dry Ginseng under Forest root 1.4kg, pulverize, be that 65% (V/V) alcohol heating reflux extracts 3 times with concentration, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use respectively successively sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction, decompression and solvent recovery gets propyl carbinol part 110g to doing;
B, separation: be that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly with the propyl carbinol that obtains, adopt trichloromethane: the eluent of methyl alcohol (V/V)=8: 1 carries out wash-out, collect 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl part elutriant, reclaim solvent and get the thick product of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl, yield 0.019%;
The purifying of c, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl: separate the 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl crude product that obtains and adopt recrystallization method to carry out purifying, get pure Ginseng under Forest saponin(e B:0.3g.
Identify: adopt method of spectroscopy to carry out Structural Identification.
The ESI-MS spectrum of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl provides: molecular weight is 799.4[M+1]
+Quasi-molecular ion peak gives m/z 637.3[M+H-glu]
+Fragment peak, and m/z 475.3[M+H-glu-glu]
+Fragment peak, in conjunction with
13CNMR,
1The HNMR spectrum determines that its molecular formula is C
42H
70O
14
1The HNMR spectrum provides 8 methyl hydrogen signal: δ 1.381 (3H, s) at High-Field, 1.300 (3H, s), 1.235 (3H, s), 1.183 (3H, s), 1.075 (6H, s), 0.805 (3H, s), 0.777 (3H, s); The midfield provides 14 proton signals of two groups of glucose, comprising anomeric proton signal δ 4.894 (1H, d, J=8.0Hz), 5.355 (1H, d, the J=7.5Hz) of two sugar and other proton signals of glucose; According to the chemical shift in conjunction with end group carbon of the coupling constant of the anomeric proton signal of glucose, two glucose are beta comfiguration as can be known; δ 3.232 (1H, dd, J=12.0,4.5Hz) is the H-3 signal, does not provide the alkene hydrogen signal; With 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-Da Ma-20S, 24S-epoxy-3 β, 12 β, 25-triol (J.P.liu, D.Lu, Y.Zhao, P.Y.Li and X.Li.A new semisynthetic ocotillol-type saponin and resuscitation of haemorrhagic shock[J] .Journal of asian natural products research, 2007,9 (2): 103-113.) relatively, former H-12 (δ 3.75) blackout, and a new signal (1H appears at δ 3.058, d, J=9.5Hz); δ 2.695 (1H, m) is the H-17 signal;
1Give other proton signal in the HNMR spectrum.
13The CNMR spectrum provides 42 carbon signals altogether; Comprise two groups of Glucose Carbon signals, be respectively δ 105.075,83.367,77.935,71.586,78.289,62.817 and 106.00,77.083,78.289,71.623,78.153,62.698; δ 88.583 is the characteristic signal of ginseng glycol saponins C-3 position; δ 56.098 is the characteristic signal of ginseng glycol saponins C-5 position; With this compound
13CNMR data and 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-Da Ma-20S, 24S-epoxy-3 β, 12 β, the data of 25-triol are compared, the side chain cyclization part that shows the two is basically identical, namely also contains the carbon signal of one group of furan nucleus in this structure.Rule (Toshinobu morita according to furans triterpenoid C-24 steric configuration, RyoJi kasai, Osamu Tanaka, et al.Saponins of Zu-Tziseng, Rhizomes of Panax Japonicus C.A.Meyer Var.major (Burk) C.Y.Wu, K.M.Feng, collected in Yunnan, China[J] .Chem.Pharm.Bull.1982,30 (12): 4341-4346.), the difference of 24R, 24S is
13The chemical shift of CNMR is different, and namely δ 85～86 is the 24R configuration, and δ 88～89 is the 24S configuration, and the C-24 chemical shift of this compound is 88.241, is the S configuration therefore judge the C-24 steric configuration of this compound.Again according to rule (the Sei Ji fuJita of furans triterpenoid C-20 steric configuration, RyoJi kasai, Kazuhiro ohtani, et al.Dammarane glycosides from aerial part of Neoalsomitra Integrifoliola[J] .Phytochemistry, 1995,39 (3): 591-602.), the key distinction of 20R, 20S is C-21's
13The CNMR chemical shift is different, and namely δ 19～20 is the 20R configuration, and δ 28～29 is the 20S configuration, and the C-21 chemical shift of this compound is δ 26.806, is the S configuration therefore judge the C-20 steric configuration of this compound.
According to
1HNMR and
13The information that CNMR spectrum provides belongs to the hydrocarbon nuclear magnetic data of this compound, the results are shown in Table 1.The hydrogen spectrum of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl (
1HNMR spectrum), the carbon spectrum (
13CNMR spectrum) and mass spectrum (ESI-MS spectrum) see respectively Fig. 1, Fig. 2 and Fig. 3 of accompanying drawing.
The NMR data of table 1 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl
Analytical results to sum up, identify that this compound is 3-O-β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl-11,12-epoxy-Da Ma-20S, 24S-epoxy-3 β, 12 β, the 25-triol (3-O-[β-D-glucopyranosyl-(1-2)-β-D-glucopyranosyl]-11,12-epoxy-dammar-20S, 24S-epoxy-3 β, 12 β, 25-triol).Through the Sciencefinder literature search, find no the report that closes this compound, be a new compound, the called after 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl.
Embodiment 2:
A, extraction: get dry Ginseng under Forest root 1.4kg, pulverize, be 75% ethanol (V/V) heating and refluxing extraction 3 times with concentration, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use respectively successively sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction, decompression and solvent recovery gets propyl carbinol part 120g to doing;
B, separation: be that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly with the propyl carbinol that obtains, adopt trichloromethane: the eluent of methyl alcohol (V/V)=2: 1 carries out wash-out, collect 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl part elutriant, reclaim solvent and get the thick product of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl, yield 0.013%;
The purifying of c, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl: separate the 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl crude product that obtains and again carry out purifying by column chromatography, get pure Ginseng under Forest saponin(e B:0.20g.
Embodiment 3:
A, extraction: get dry Ginseng under Forest root 1.4kg, pulverize, be 85% ethanol (V/V) heating and refluxing extraction 3 times with concentration, be respectively 3h, 2h, 1h at every turn, filter united extraction liquid, be evaporated to relative density 1.12～1.15, use respectively successively sherwood oil, trichloromethane, ethyl acetate, n-butanol extraction, decompression and solvent recovery gets propyl carbinol part 100g to doing.
B, separation: be that 200～300 purpose column chromatography silica gels carry out column chromatography for separation with specification partly with the propyl carbinol that obtains, adopt trichloromethane: the eluent of methyl alcohol (V/V)=1: 1 carries out wash-out, collect 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl part elutriant, reclaim solvent and get the thick product of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl, yield 0.016%;
The purifying of c, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl: separate the 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl crude product that obtains and adopt preparative liquid chromatography to carry out purifying, get pure Ginseng under Forest saponin(e B:0.23g.
The present invention can further specify by following experimental example.
Experimental example one, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl are on the impact of hemorrhagic shock
One, experiment material and method
Material: 6 of domesticated dogs; 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl is hereinafter to be referred as the PGGB:10mg/ml aqueous solution
Method: dog with Nembutal vein anesthetic (1ml), is lain on the back and is fixed on the operating table, separate tracheae, insert trachea cannula.Separate arteria carotis communis, connect RM-6000 four and lead physiograph, survey: BP (SBP/DBP); Separate right side bone artery, survey LVSP, LVEDP, ± dp/dt; Separate the right lateral thigh vein, standby administrable.
Separate Right deviation side femoral artery, standby arterial blood letting usefulness connects cardiac diagnosis lead, survey ECG and calculate HR, xiphoid-process skin place connects force transducer with silk thread, surveys respiratory rate, perform the operation complete after, stablized 10 minutes, and recorded every normal index, then store in the blood bottle to filling 0.1% heparin-saline through the femoral artery bloodletting, making the artery average pressure drop is that shock is (after bloodletting to 40mmHg, BP sharply descends, and can with in the defeated object that reverses of blood, make the artery mean pressure maintain 40mmHg).Stablized 20 minutes, the artery mean pressure does not rise, and presses the 10mg/kgb administration, and observe 120 minutes indices and change, after the record administration 1,3,5,10,20,30,45,60,90,120 minutes.Venous blood collection, centrifugal, get serum, measure LPO (Ba Mushi improved method) and SOD.
Two, experimental result
1, on the impact of mean arterial blood pressure (MBP)
3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl (PGGB) small dose group 20 ', 30 ' MBP after administration significantly raises, and compares with the saline control group, and notable difference (p＜0.05) is arranged.The rising percentage of 5 '～45 ' MBP is compared for two groups apparently higher than the saline control group, significant difference (p＜0.05, p＜0.01, p＜0.001).
The heavy dose of group of PGGB 5 '～120 ' MBP and rising percentage after administration are very significant all apparently higher than saline control group (p＜0.05, p＜0.01, p＜0.001).
Dopamine HCL group 5 '～20 ' MBP after administration obviously raises, and the rising percentage of 5 '～30 ' MBP is compared with the salt solution group variant significantly (p＜0.05, p＜0.01) apparently higher than the saline control group.The results are shown in Table 1-1.
Table .1-1 PGGB is on the impact of MBP (Kpa)
Continued 1-1
Continued .1-1
*P＜0.05,
*P＜0.01,
* *Compare with the 0.9%NaCl control group p＜0.001.
2, on the impact of+dp/dt
The PGGB small dose group after administration 10 '～45 ' and 90 ', 120 '+dp/dt obviously increases the significant difference of comparing with the saline control group (p＜0.05, p＜0.01).The rising percentage of 30 '～120 '+dp/dt is significantly higher than the saline control group, compares that there were significant differences (p＜0.05, p＜0.01) for two groups.
The heavy dose of group of PGGB is 30 '～120 '+dp/dt and all significantly increases of rising percentage after administration, compare with the saline control group and are very significant (p＜0.05, p＜0.01).
The Dopamine HCL group is 5 '～45 '+dp/dt and all significantly increases of rising percentage after administration, compare significant difference (p＜0.05, p＜0.01, p＜0.001) with the saline control group.The results are shown in Table 1-2.
Table 1-2 PGGB is on the impact of+dp/dt (Kpa/s)
Continued 1-2
Continued 1-2
Continued 1-2
Continued 1-2
P＜0.05,
*P＜0.01,
* *Compare with the 0.9%NaCl control group p＜0.001.
3, the impact of p-dp/dt
The rising percentage of PGGB small dose group 45 '-dp/dt after administration is apparently higher than the saline control group, the significant difference (p＜0.05) of comparing with the saline control group.
The heavy dose of group of PGGB 60 '-dp/dt after administration obviously raises, and the rising percentage of 10 '～60 '-dp/dt is compared (p＜0.05, p＜0.01) for two groups apparently higher than the saline control group.
Dopamine HCL group 5 ', 10 '-dp/dt after administration compares significant difference (p＜0.01) apparently higher than the saline control group with the saline control group.The rising percentage of 5 '～20 '-dp/dt is compared significant difference (p＜0.05, p＜0.01) apparently higher than the saline control group with the saline control group.The results are shown in Table 1-3.
The impact of the table p-dp/dt of 1-3 PGGB (Kpa/s)
Continued 1-3
Continued 1-3
Continued 1-3
Continued 1-3
*P＜0.05,
*Compare with the 0.9%NaCl control group p＜0.01.
Heart rate and respiratory rate: compare no significant difference when each time point is with shock after administration.
The result shows: 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl (PPGB) has the anti-hemorrhagic shock effect.
Experiment two, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl are on the hemodynamic impact of Normal Anesthetized Dogs (n=6)
One, experiment material and method
Material: 6 of domesticated dogs, body weight 13kg～15kg body weight, each 3 of male and female, 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl: 10mg/ml solution;
Method: method is with experiment one, therefore slightly.
Two, result
1, on the impact of lipid peroxide (LPO)
Little, the heavy dose of group of PGGB content of 120 ' LPO after administration is starkly lower than the saline control group, two groups of comparing differences remarkable (p＜0.05).
The content of Dopamine HCL group 120 ' LPO after administration is starkly lower than the saline control group, two groups of comparing differences remarkable (p＜0.05).The results are shown in Table 2-1.
Table 2-1 PGGB is on the impact of LPO (A/ml)
Compare with the 0.9%NaCl control group p＜0.05.
2, on the impact of superoxide-dismutase (SOD)
The content of PGGB small dose group 120 ' SOD after administration and percentage and saline control group are relatively without significant difference.
The content of the heavy dose of group of PGGB 120 ' SOD after administration and rising percentage be apparently higher than the saline control group, and two groups of comparing differences are (p＜0.05, p＜0.01) significantly.
The content of Dopamine HCL group 120 ' SOD after administration and rising percentage are apparently higher than the saline control group, and two groups of comparing differences remarkable (p＜0.01) the results are shown in Table 2-2.
Table 2-2 PGGB is on the impact of SOD (U/l)
*P＜0.05,
*Compare with the NaCl control group p＜0.01.
The result shows: 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl can significantly reduce LPO and improve SOD content, and anti-radical action is arranged.
The embodiment one of preparation medicament:
3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl 35g, 1,2-PD 10000ml, in 1000 ampullas of packing into after the mixing, every 10ml contains 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl 35mg.
The embodiment two of preparation medicament:
3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl 20.0g, medical starch 480g, the two fully mixes, and is encapsulated, makes 1000 capsules, and every heavy 0.5g contains 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl 20mg.
Claims (1)
- One kind as shown in the formula the application of 3-O-[BETA-D-glucopyranosyl-(1-2)-BETA-D-glucopyranosyl in the medicine of preparation treatment ischemic shock,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010555974 CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010555974 CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102050864A CN102050864A (en) | 2011-05-11 |
| CN102050864B true CN102050864B (en) | 2013-01-02 |
Family
ID=43955708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010555974 Expired - Fee Related CN102050864B (en) | 2010-11-24 | 2010-11-24 | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102050864B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106805243A (en) * | 2017-02-28 | 2017-06-09 | 吉林省清评科技有限公司 | A kind of high-valued method of comprehensive utilization of Ginseng under Forest |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518540A (en) * | 2009-03-27 | 2009-09-02 | 吉林华康药业股份有限公司 | Medical composition |
-
2010
- 2010-11-24 CN CN 201010555974 patent/CN102050864B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518540A (en) * | 2009-03-27 | 2009-09-02 | 吉林华康药业股份有限公司 | Medical composition |
Non-Patent Citations (2)
| Title |
|---|
| J.P.liu,et al..A new semisynthetic ocotillol-type saponin and resuscitation of haemorrhagic shock.《Journal of Asian Natural Products Research》.2007,第9卷(第2期),第106-107页. * |
| 钟方丽.林下参化学成分及其生物活性的研究.《医药卫生科技辑》.2008,第二章2.5.1.1中的化合物22,第二章2.3,第五章实验部分5.3.2.4. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102050864A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103040882B (en) | Passiflora edulis sims stem-leaf extract as well as pharmaceutical composition and antidepressant action of extract | |
| CN102526353B (en) | A kind of preparation method for the treatment of the drug combination preparation of myocardial ischemia | |
| CN101880304A (en) | 24(R)-pseudoginsenoside-GQ as well as semisynthesis method and medicinal application thereof | |
| CN101485700B (en) | Refined cherimoya total inner ester with anti-tumor activity and preparation method thereof | |
| EP1559703B1 (en) | A natural compound useful for treating diabetes, its preparation and use | |
| CN113789214A (en) | Compound ganoderma lucidum spore oil for improving cancer-induced fatigue and preparation method and application thereof | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN102050864B (en) | Transplanted wild ginseng ginsenoside B as well as extraction method and medical application thereof | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102614276A (en) | Dahurian rose fruit leaf general flavone extract, and extracting method and medical application thereof | |
| CN103360452A (en) | Preparation and application of pedicellus melo tetracyclic triterpenoid cucurbitacin type compound | |
| CN104693262B (en) | Da Ma-20S, 25S-epoxy-3 β, 12 β, 26-triols and extracting method thereof and medicinal usage | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN105418722B (en) | A kind of entitled Sasanguasaponin C4And C5Pentacyclic triterpenoid preparation method | |
| CN101948498B (en) | Pseudo-ginsenoside G2, extraction method and drug application thereof | |
| CN101156882A (en) | Preparation method of pseudo-ginseng protopanoxadiol saponin and its uasage | |
| CN109303785B (en) | Application of lobetyolin analog compound in preparation of medicine for treating arrhythmia | |
| CN104257756B (en) | The application in preparing hypoglycemic medicine of a kind of Cortex Mori fatty oil | |
| CN1488355A (en) | Cough-relieving chinese medicine formulation of total glycoside of mango leaf | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN101863945B (en) | American ginseng saponin F6 as well as extraction method and medical application thereof | |
| CN101928320B (en) | American ginseng ginsenoside F5ab and extraction method and medicinal application thereof | |
| JPH0481570B2 (en) | ||
| CN116554254B (en) | Compound with sedative and insomnia relieving effects and application thereof | |
| CN100546589C (en) | The preparation of caterpillar fungus cephalosporin powder anti-arrhythmia effective part and pharmaceutical preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130102 Termination date: 20181124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |